They invest large sums in research and the development of new drugs, primarily for pain therapy as well as for the field of oncology, the fastest-growing segment of their industry in terms of sales. Pharmaceutical manufacturers have long come to terms with these overall conditions. Once patent protection expires, sales drop dramatically. The time span for profits is therefore identical to the life of the patent.
Pharmaceutical manufacturers have long come to terms with these overall conditions. The current restrictions resulting from the energy crisis are also causing problems for the entire industry, as they require a high degree of flexibility and innovative ideas in order to remain profitable. Many basic products were derived from the chemical industry, which has drastically reduced its production due to the increase in energy prices.
It is particularly critical in these times of uncertainty to eliminate additional critical components. No pharmaceutical company can afford to have vacant C-level positions at present. The risk of suffering a slump in the generation of added value is far too great. It is here, therefore, that the assignment of an interim manager offers clear advantages and makes it possible to act in a structured and goal-oriented manner even in difficult times.